Ashwani Verma
Stock Analyst at UBS
(3.30)
# 1,131
Out of 4,412 analysts
38
Total ratings
53.57%
Success rate
1.82%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | $59 → $60 | $38.97 | +53.96% | 2 | Apr 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $76 → $81 | $45.30 | +78.81% | 2 | Mar 18, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $135 → $131 | $109.46 | +19.68% | 4 | Mar 1, 2024 | |
| ALKS Alkermes | Downgrades: Sell | $25 | $24.68 | +1.30% | 2 | Feb 20, 2024 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $111 | $71.71 | +54.79% | 1 | Feb 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $21 | $17.81 | +17.91% | 1 | Feb 6, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $61 → $92 | $65.34 | +40.80% | 4 | Jan 24, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $74 → $82 | $73.26 | +11.93% | 3 | Jan 2, 2024 | |
| TEVA Teva Pharmaceutical | Upgrades: Buy | $11 → $13 | $13.81 | -5.87% | 4 | Nov 27, 2023 | |
| ACLX Arcellx | Initiates: Buy | $52 | $51.92 | +0.15% | 1 | Oct 17, 2023 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Buy | $33 | $16.71 | +97.49% | 1 | Oct 17, 2023 | |
| COHR Coherent | Maintains: Buy | $11 → $7 | $55.06 | -87.29% | 1 | Aug 7, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $121 → $115 | $135.99 | -15.43% | 3 | Jul 13, 2023 | |
| UTHR United Therapeutics | Maintains: Buy | $330 → $310 | $233.85 | +32.56% | 2 | Apr 10, 2023 | |
| CHRS Coherus BioSciences | Upgrades: Buy | $11 | $2.04 | +439.22% | 2 | Mar 28, 2023 | |
| RPRX Royalty Pharma | Maintains: Buy | $51 → $48 | $28.00 | +71.43% | 2 | Feb 16, 2023 | |
| VTRS Viatris | Upgrades: Neutral | $9 → $12 | $11.57 | +3.72% | 2 | Nov 10, 2022 | |
| RANI Rani Therapeutics Holdings | Initiates: Buy | $15 | $6.68 | +124.55% | 1 | Oct 11, 2022 |
Biohaven Pharmaceutical Holding Company
Apr 23, 2024
Maintains: Buy
Price Target: $59 → $60
Current: $38.97
Upside: +53.96%
Legend Biotech
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $45.30
Upside: +78.81%
Jazz Pharmaceuticals
Mar 1, 2024
Maintains: Neutral
Price Target: $135 → $131
Current: $109.46
Upside: +19.68%
Alkermes
Feb 20, 2024
Downgrades: Sell
Price Target: $25
Current: $24.68
Upside: +1.30%
Axsome Therapeutics
Feb 6, 2024
Initiates: Buy
Price Target: $111
Current: $71.71
Upside: +54.79%
Avadel Pharmaceuticals
Feb 6, 2024
Initiates: Buy
Price Target: $21
Current: $17.81
Upside: +17.91%
Cytokinetics
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $65.34
Upside: +40.80%
Intra-Cellular Therapies
Jan 2, 2024
Maintains: Buy
Price Target: $74 → $82
Current: $73.26
Upside: +11.93%
Teva Pharmaceutical
Nov 27, 2023
Upgrades: Buy
Price Target: $11 → $13
Current: $13.81
Upside: -5.87%
Arcellx
Oct 17, 2023
Initiates: Buy
Price Target: $52
Current: $51.92
Upside: +0.15%
ACADIA Pharmaceuticals
Oct 17, 2023
Initiates: Buy
Price Target: $33
Current: $16.71
Upside: +97.49%
Coherent
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $55.06
Upside: -87.29%
Neurocrine Biosciences
Jul 13, 2023
Maintains: Buy
Price Target: $121 → $115
Current: $135.99
Upside: -15.43%
United Therapeutics
Apr 10, 2023
Maintains: Buy
Price Target: $330 → $310
Current: $233.85
Upside: +32.56%
Coherus BioSciences
Mar 28, 2023
Upgrades: Buy
Price Target: $11
Current: $2.04
Upside: +439.22%
Royalty Pharma
Feb 16, 2023
Maintains: Buy
Price Target: $51 → $48
Current: $28.00
Upside: +71.43%
Viatris
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.57
Upside: +3.72%
Rani Therapeutics Holdings
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $6.68
Upside: +124.55%